Simeprevir (Olysio®)

Assessment Status Assessment Process Complete
Drug Simeprevir
Brand Olysio®
Indication In combination with Sofosbuvir for the treatment of chronic hepatitis C (CHC) in adult patients who are intolerant to or ineligible for interferon therapy, and are in urgent need of treatment.
Assessment Process
Rapid review commissioned 27/05/2014
Rapid review completed 11/07/2014
Rapid review outcome Full Pharmacoeconomic Evaluation Recommended
Full submission received from Applicant 30/10/2014
Preliminary review sent to Applicant 13/03/2015
NCPE assessment outcome Reimbursement recommended in some subgroups

The NCPE recommends reimbursement of simeprevir in combination with sofosbuvir for genotype 1 in some subgroups

Technical Summary